Why do people switch away from cobicistat-boosted protease inhibitors?

被引：0
|
作者：
Byrne, L. [1 ]
Kabagambe, S. [1 ]
Awosusi, F. [1 ]
Sarner, L. [1 ]
机构：
[1] Barts Hlth NHS Trust, London, England
来源：
HIV MEDICINE | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P34
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [1] Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir
    Pickering, Richard Taylor
    Asundi, Archana
    Olson, Alex
    Soden, Katie
    Kuritzkes, Daniel R.
    Lin, Nina H.
    ANTIVIRAL THERAPY, 2025, 30 (01)
  • [2] Cobicistat-Boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment
    McDonald, Cheryl K.
    Martorell, Claudia
    Ramgopal, Moti
    Laplante, Francois
    Fisher, Martin
    Post, Frank A.
    Liu, Yapei
    Curley, Joanne
    Abram, Michael E.
    Custodio, Joseph
    Graham, Hiba
    Rhee, Martin S.
    Szwarcberg, Javier
    HIV CLINICAL TRIALS, 2014, 15 (06): : 269 - 273
  • [3] EXTRAPOLATION OF DACLATASVIR DOSING RECOMMENDATIONS FROM RITONAVIR BOOSTED PROTEASE INHIBITORSTO COBICISTAT PROTEASE INHIBITORS
    Gandhi, Y.
    Wang, Q.
    Li, W.
    Eley, T.
    Zheng, M.
    LaCreta, F.
    Bertz, R.
    Garimella, T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S65 - S65
  • [4] Management of Antiretroviral Therapy with Boosted Protease Inhibitors - Darunavir/Ritonavir or Darunavir/Cobicistat
    Marin, Ruxandra-Cristina
    Behl, Tapan
    Negrut, Nicoleta
    Bungau, Simona
    BIOMEDICINES, 2021, 9 (03)
  • [5] Cost-effectiveness switching from ritonavir-to cobicistat-boosted PIs: is simplification as straightforward as it sounds?
    Colver, H.
    Sobo, T.
    Turner, J.
    HIV MEDICINE, 2018, 19 : S23 - S23
  • [6] Effectiveness, Safety, and Tolerability of a Switch to Dual Therapy with Dolutegravir Plus Cobicistat-Boosted Darunavir in Treatment-Experienced Patients with Human Immunodeficiency Virus
    Lee, Sang-Ah
    Kim, Shin-Woo
    Chang, Hyun-Ha
    Jung, Hyejin
    Kim, Yoonjung
    Hwang, Soyoon
    Kim, Sujeong
    Park, Han-Ki
    Lee, Jong-Myung
    INFECTION AND CHEMOTHERAPY, 2018, 50 (03): : 252 - 262
  • [7] Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran
    Kakadiya, Payal P.
    Higginson, Robert T.
    Fulco, Patricia Pecora
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (02)
  • [8] Darunavir/cobicistat as antiretroviral treatment simplification strategy in patients with stable monotherapy with ritonavir-boosted protease inhibitors in the clinical setting
    Ramon Santos, Jose
    Pelaez Ibanez, Pablo
    Bravo, Isabel
    Maria Llibre, Josep
    Paredes, Roger
    Clotet, Bonaventura
    Molto, Jose
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [9] Why do people switch mobile platforms? The moderating role of habit
    Lin, Kuan-Yu
    Wang, Yi-Ting
    Hsu, Hsuan-Yu Sheila
    INTERNET RESEARCH, 2017, 27 (05) : 1170 - 1189
  • [10] Why Do Some Boys Run Away from Home?
    Tiwari P.A.
    Gulati N.
    Sethi G.R.
    Mehra M.
    The Indian Journal of Pediatrics, 2002, 69 (5) : 397 - 399
12345